T
67.76
2.97 (4.58%)
| 前收盘价格 | 64.79 |
| 收盘价格 | 64.79 |
| 成交量 | 902,926 |
| 平均成交量 (3个月) | 970,372 |
| 市值 | 2,973,511,936 |
| 预期市盈率 (P/E Forward) | 106.38 |
| 价格/销量 (P/S) | 4.71 |
| 股市价格/股市净资产 (P/B) | 7.38 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -44.91% |
| 营业利益率 (TTM) | -33.55% |
| 稀释每股收益 (EPS TTM) | -2.70 |
| 季度收入增长率 (YOY) | 183.70% |
| 总债务/股东权益 (D/E MRQ) | 21.13% |
| 流动比率 (MRQ) | 5.57 |
| 营业现金流 (OCF TTM) | -65.89 M |
| 杠杆自由现金流 (LFCF TTM) | -36.41 M |
| 资产报酬率 (ROA TTM) | -16.05% |
| 股东权益报酬率 (ROE TTM) | -33.98% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Tarsus Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.33 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.25% |
| 机构持股比例 | 110.77% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Deep Track Capital, Lp | 31 Mar 2026 | 3,600,000 |
| Rtw Investments, Lp | 31 Mar 2026 | 3,346,025 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 2,562,154 |
| Janus Henderson Group Ltd. | 31 Mar 2026 | 2,240,963 |
| Jennison Associates Llc | 30 Jun 2026 | 1,663,655 |
| Tang Capital Management Llc | 31 Mar 2026 | 1,188,624 |
| Assenagon Asset Management S.A. | 30 Jun 2026 | 947,495 |
| Driehaus Capital Management Llc | 31 Mar 2026 | 926,125 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合